Macrogenics Q1 2024 GAAP EPS $(0.84) Misses $(0.61) Estimate, Sales $9.104M Miss $14.617M Estimate
Portfolio Pulse from Benzinga Newsdesk
Macrogenics (NASDAQ:MGNX) reported Q1 2024 GAAP EPS of $(0.84), missing the $(0.61) estimate, with sales of $9.104M also missing the $14.617M estimate. This represents a 37.7% decrease in EPS and a 62.83% decrease in sales from the same period last year.
May 09, 2024 | 8:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Macrogenics reported a significant miss in both EPS and sales for Q1 2024, with a 37.7% decrease in EPS and a 62.83% decrease in sales year-over-year.
The significant miss in both EPS and sales compared to analyst estimates and the substantial decrease from the previous year's figures are likely to negatively impact investor sentiment and the stock price of Macrogenics in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100